All Archives - BaseLaunch

All

Looking for an experienced biopharma professional for CEO role

One of our preclinical companies is currently looking for an experienced biopharma entrepreneurial-minded CEO. The company specializes in engineering next-generation biologics to rebalance the immune…

andy11.12.2024

All Portfolio news

Polyneuron Pharmaceuticals granted the FDA orphan drug designation

The orphan drug designation can only be granted for treatments on rare diseases to advance the developments of safe and effective therapies and the FDA…

clement19.08.2020

female laboratory worker looking into microscope

All Portfolio news

PharmaBiome secures CHF 1.75 million

PharmaBiome also welcomed two new board members with extensive biotech and entrepreneurial experience, all the way from founding to IPO. Dr. Thomas Meier joins PharmaBiome…

clement19.08.2020

Scientist in a Lab Coat looking at Laboratory samples

All Features

News bulletin: CSL Behring becomes BaseLaunch partner for Phase II

We are very pleased to welcome CSL Behring, one of the largest biotech companies in the world, as a partner in BaseLaunch Phase II. Read the…

clement30.07.2020

Female scientist working in a laboratory

All Portfolio news

T3 Pharma raises over 25 million Swiss francs

T3 Pharmaceuticals (T3 Pharma) has successfully closed a third financing round, raising over 25 million Swiss francs. According to a press release, the financing was co-led…

Emma Bulmer27.07.2020

All Features

Bridge Biotherapeutics becomes BaseLaunch’s first Asia Pacific partner

Special Report: The latest addition to the partner portfolio all the way from Asia Pacific. A warm welcome to Bridge Biotherapeutics, for which CEO, James Lee,…

clement14.07.2020

All Features

News flash: Roivant Sciences continues partnership

We welcome back Roivant Sciences with open arms for the continuation of their partnership with BaseLaunch Phase II. Sascha Bucher, Head of Global Transactions at…

clement24.06.2020

All Portfolio news

New partner announcement: BB Pureos Bioventures

We are proud to announce that BB Pureos Bioventures has become a partner in BaseLaunch Phase II as the first venture capital fund. Anja Harmeier,…

clement08.06.2020

All Features

Roche becomes a founding partner of BaseLaunch Phase II

We are proud to announce that Roche has become a founding partner in the next phase of BaseLaunch. With this commitment, Roche renews its partnership…

clement15.05.2020

All Portfolio news

Polyneuron recieves approval to begin clinical study

Congratulations to one of BaseLaunch’s portfolio companies, Polyneuron on their latest milestone: First clinical trial application approval. Wishing you great success with the studies later…

clement11.05.2020

All

Looking for an experienced biopharma professional for CEO role

Polyneuron Pharmaceuticals granted the FDA orphan drug designation

PharmaBiome secures CHF 1.75 million

News bulletin: CSL Behring becomes BaseLaunch partner for Phase II

T3 Pharma raises over 25 million Swiss francs

Bridge Biotherapeutics becomes BaseLaunch’s first Asia Pacific partner

News flash: Roivant Sciences continues partnership

New partner announcement: BB Pureos Bioventures

Roche becomes a founding partner of BaseLaunch Phase II

Polyneuron recieves approval to begin clinical study

Useful links

Contact us

Sign up for our newsletter and event invitations

Follow us